Evidence map›Paper›PMID 28223801›Full record

ReviewInternational journal of nanomedicine2017

Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus - current status.

Palanivel Ganesan, Palanisamy Arulselvan, Dong-Kug Choi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Current developments in the nanomediated delivery of photoprotective phytochemicals.Environmental science and pollution research international · 2020
    Review
  12. The Antioxidant Activities ofAntioxidants (Basel, Switzerland) · 2020
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Nanodelivery of Natural Antioxidants: An Anti-aging Perspective.Frontiers in bioengineering and biotechnology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Palanivel GanesanNanotechnology Research Center and Department of Applied Life Science; Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea.
Palanisamy ArulselvanLaboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia.
Dong-Kug ChoiNanotechnology Research Center and Department of Applied Life Science; Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, Republic of Korea.
Konkuk University · KRUniversiti Putra Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a major chronic disease that is prevalent worldwide, and it is characterized by an increase in blood glucose, disturbances in the metabolism, and alteration in insulin secretion. Nowadays, food-based therapy has become an important treatment mode for type 2 diabetes, and phytobioactive compounds have gained an increasing amount of attention to this end because they have an effect on multiple biological functions, including the sustained secretion of insulin and regeneration of pancreatic islets cells. However, the poor solubility and lower permeability of these phyto products results in a loss of bioactivity during processing and oral delivery, leading to a significant reduction in the bioavailability of phytobioactive compounds to treat T2DM. Recently, nanotechnological systems have been developed for use as various types of carrier systems to improve the delivery of bioactive compounds and thus obtain a greater bioavailability. Furthermore, carrier systems in most nanodelivery systems are highly biocompatible, with nonimmunologic behavior, a high degree of biodegradability, and greater mucoadhesive strength. Therefore, this review focuses on the various types of nanodelivery systems that can be used for phytobioactive compounds in treating T2DM with greater antidiabetic effects. There is also additional focus on improving the effects of various phytobioactive compounds through nanotechnological delivery to ensure a highly efficient treatment of type 2 diabetes.

Indexed as

Drug Delivery SystemsAnimalsDiabetes Mellitus, Type 2HumansHypoglycemic AgentsNanoparticlesPlant ExtractsHypoglycemic AgentsPlant Extractsnanodelivery systemoral deliveryphytobioactive compoundstype 2 diabetes

Identifiers

PMID28223801
PMCPMC5310641
OpenAlexW2587657510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.